Evidence map›Paper›PMID 29322062›Full record

ArticleOpen forum infectious diseases2018

Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.

Sarah L Pett, Ken M Kunisaki, Deborah Wentworth, Timothy J Griffin, Ioannis Kalomenidis, Raquel Nahra, Rocio Montejano Sanchez, Shane W Hodgson, Kiat Ruxrungtham, Dominic Dwyer and 3 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01056185 (An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01056185 completednot on this map

An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses

TypeobservationalSponsorUniversity of MinnesotaRan2009 to 2024Enrolled1,000ConditionsInfluenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Kynurenine Pathway in Respiratory Diseases.International journal of tryptophan research : IJTR · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Metabolomics as a Tool to Investigate HIV/TB Co-Infection.Frontiers in molecular biosciences · 2021
    Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 6 countries.

Sarah L PettMedical Research Council Clinical Trials Unit (MRC CTU), Institute of Clinical Trials and Methodology, University College London, UK.
Ken M KunisakiMinneapolis VA Health Care System, Minneapolis, Minnesota.
Deborah WentworthDivision of Biostatistics, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota.
Timothy J GriffinDepartment of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, Minnesota.
Ioannis Kalomenidis1st Department of Critical Care and Pulmonary Medicine, University of Athens School of Medicine, Evangelismos General Hospital, Athens, Greece.
Raquel NahraCooper University Hospital, Division of Infectious Disease, Camden, New Jersey.
Rocio Montejano SanchezHospital La Paz, Madrid, Spain.
Shane W HodgsonMinneapolis VA Health Care System, Minneapolis, Minnesota.
Kiat RuxrungthamHIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand.
Dominic DwyerInstitute of Clinical Pathology and Medical Research, Pathology West and NSW Health Pathology, Westmead Hospital and University of Sydney, Westmead, Australia.
Richard T DaveyNational National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Chris H WendtMinneapolis VA Health Care System, Minneapolis, Minnesota.
INSIGHT FLU003 Plus Study Group
University of Minnesota · USChulalongkorn University · THThe University of Sydney · AUUNSW Sydney · AUNational Institutes of Health · USCooper University Hospital · USHospital Universitario La Paz · ESMinneapolis VA Health Care System · USNational and Kapodistrian University of Athens · GR

Funding

Influenza and Emerging Infectious DiseasesZIAAI000984 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DAVEY, RICHARD · 2009 to 2025
$44.1M
CCR NIH HHS HHSN261200800001CMedical Research Council MC_UU_12023/22NCI NIH HHS HHSN261200800001ENCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003I
6 · The paper itself

Abstract

backgroundIndoleamine-2,3-dioxygenase (IDO) mediated tryptophan (TRP) depletion has antimicrobial and immuno-regulatory effects. Increased kynurenine (KYN)-to-TRP (KT) ratios, reflecting increased IDO activity, have been associated with poorer outcomes from several infections.

methodsWe performed a case-control (1:2; age and sex matched) analysis of adults hospitalized with influenza A(H1N1)pdm09 with protocol-defined disease progression (died/transferred to ICU/mechanical ventilation) after enrollment (cases) or survived without progression (controls) over 60 days of follow-up. Conditional logistic regression was used to analyze the relationship between baseline KT ratio and other metabolites and disease progression.

resultsWe included 32 cases and 64 controls with a median age of 52 years; 41% were female, and the median durations of influenza symptoms prior to hospitalization were 8 and 6 days for cases and controls, respectively (

conclusionsHigh KT ratio was associated with poor outcome in adults hospitalized with influenza A(H1N1)pdm09. The clinical utility of this biomarker in this setting merits further exploration. CLINICALTRIALSGOV IDENTIFIER: NCT01056185.

Indexed as

indoleamine-2,3-dioxygenaseinfluenzakynurenineoutcometryptophan

Identifiers

PMID29322062
PMCPMC5753217
OpenAlexW2786635147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.